Alpha Blue Ocean, Pharnext Strike Deal on PXT3003 Study

Alpha Blue Ocean, Pharnext Strike Deal on PXT3003 Study

296475

Alpha Blue Ocean, Pharnext Strike Deal on PXT3003 Study

A new financial partnership between Pharnext and Alpha Blue Ocean will help support the Phase 3 clinical trial PREMIER, which is testing Pharnext’s investigational therapy PXT3003 for Charcot-Marie-Tooth disease type 1A (CMT1A). CMT1A is the most common subtype of CMT type 1, which is the most common type of CMT. CMT1A is caused by a genetic mutation that leads to excessive production of the PMP22 protein. Excess levels of this protein lead to a loss of…

You must be logged in to read/download the full post.